Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: Synthetic and biological studies

Journal of Medicinal Chemistry

Volumn 55, Issue 1, 2012, Pages 558-562

  Rodrigo, Christina M ^a   Cencic, Regina ^b   Roche, Stéphane P ^a   Pelletier, Jerry ^b   Porco, John A ^a  

^a Boston University   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HYDROXAMIC ACID DERIVATIVE; INITIATION FACTOR; METHYL ROCAGLATE; N METHOXY ROCAGLAMIDE; SILVESTROL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG IDENTIFICATION; DRUG SYNTHESIS; EX VIVO STUDY; IN VITRO STUDY; LYMPHOMA; PROTEIN SYNTHESIS;

EID: 84855855153     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201263k     Document Type: Article

References (20)

1. Hwang, B. Y.; Su, B. N.; Chai, H.; Mi, Q.; Kardono, L. B. S.; Afriastini, J. J.; Riswan, S.; Santarsiero, B. D.; Mesecar, A. D.; Wild, R.; Fairchild, C. R.; Vite, G. D.; Rose, W. C.; Farnsworth, N. R.; Cordell, G. A.; Pezzuto, J. M.; Swanson., S. M.; Kinghorn, A. D. Silvestrol and Episilvestrol, Potential Anticancer Rocaglate Derivatives from Aglaia silvestris J. Org. Chem. 2004, 69, 3350-3358
2. Malina, A.; Cencic, R.; Pelletier, J. Targeting translation dependence in cancer Oncotarget 2011, 2, 76-88
3. 2/M Checkpoint Genes Independent of p53 Activity Anticancer Res. 2006, 26, 3349-3356
4. Bordeleau, M.-E.; Robert, F.; Gerard, B.; Lindqvist, L.; Chen, S. M. H.; Wendel, H.-G.; Brem, B.; Greger, H.; Lowe, S. W.; Porco, J. A., Jr.; Pelletier, J. Therapeutic suppression of translation initiation modulates chemoselectivity in a mouse lymphoma model J. Clin. Invest. 2008, 118, 2651-2660
5. Silvera, D.; Formenti, S. C.; Schneider, R. Translational control in cancer J. Natl. Rev. Cancer 2010, 10, 254-266
6. Gerard, B.; Cencic, R.; Pelletier, J.; Porco, J. A., Jr. Enantioselective Synthesis of the Complex Rocaglate (-)-Silvestrol Angew. Chem., Int. Ed. 2007, 46, 7831-7834
7. Adams, T. E.; El Sous, M.; Hawkins, B. C.; Hirner, S.; Holloway, G.; Khoo, M. L.; Owen, D. J.; Savage, G. P.; Scammela, P. J.; Rizzacasa, M. A. Total Synthesis of the Potent Anticancer Aglaia Metabolites (-)-Silvestrol and (-)-Episilvestrol and the Active Analogue (-)-4′-Desmethoxyepisilvestrol J. Am. Chem. Soc. 2009, 131, 1607-1616
8. Thuaud, F.; Bernard, Y.; Turkeri, G.; Dirr, R.; Aubert, G.; Cresteil, T.; Baguet, A.; Tomasetto, C.; Svitkin, Y.; Sonenberg, N.; Nebigil, C. G.; Desaubry, L. Synthetic Analogue of Rocaglaol Displays a Potent and Selective Cytotoxicity in Cancer Cells: Involvement of Apoptosis Inducing Factor and Caspase-12 J. Med. Chem. 2009, 52, 5176-5187
9. Thuaud, F.; Ribeiro, N.; Gaiddon, C.; Cresteil, T.; Desaubry, L. Novel Flavaglines Displaying Improved Cytotoxicity J. Med. Chem. 2011, 54, 411-415
10. For potential insecticidal activity of 3, see: Dobler, M. R.; Bruce, I.; Cederbaum, F.; Cooke, N. G.; Diorazio, L. J.; Hall, R. G.; Irving, E. Total synthesis of (±)-rocaglamide and some aryl analogues Tetrahedron Lett. 2001, 42, 8281-8284
11. Roche, S. P.; Cencic, R.; Pelletier, J.; Porco, J. A., Jr. Biomimetic Photocycloaddition of 3-Hydroxyflavones: Synthesis and Evaluation of Rocaglate Derivatives as Inhibitors of Eukaryotic Translation Angew. Chem., Int. Ed. 2010, 49, 6533-6538
12. Gu, X.; Wang, Y.; Kumar, A.; Ye, G.; Parang, K.; Sun, G. Design and Evaluation of Hydroxamate Derivatives as Metal-Mediated Inhibitors of a Protein Tyrosine Kinase J. Med. Chem. 2006, 49, 7532-7539
13. Mansoor, U. F.; Vitharana, D.; Reddy, P. A.; Daubaras, D. L.; McNicholas, P.; Orth, P.; Black, T.; Siddiqui, M. A. Design and synthesis of potent Gram-negative specific LpxC inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 1155-1161
14. Tecle, H.; Shao, J.; Li, Y.; Kothe, M.; Kazmirski, S.; Penzotti, J.; Ding, Y.-H.; Ohren, J.; Moshinsky, D.; Coli, R.; Jhawar, N.; Bora, E.; Jacques-OHagan, S.; Wu, J. Beyond the MEK-pocket: Can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK pocket exist in kinases other than MEK? Bioorg. Med. Chem. Lett. 2009, 19, 226-229 and references therein
15. Mo, F.; Yan, J. M.; Qiu, D.; Li, F.; Zhang, Y.; Wang, J. Gold-Catalyzed Halogenation of Aromatics by N -Halosuccinimides Angew. Chem., Int. Ed. 2010, 49, 2028-2032
16. Gerard, B.; Sangji, S.; OLeary, D. J.; Porco, J. A., Jr. Enantioselective Photocycloaddition mediated by Chiral Bronsted Acids: Asymmetric Synthesis of the Rocaglamides J. Am. Chem. Soc. 2006, 128, 7754-7755
17. Marsilje, T. H.; Hedrick, M. P.; Desharnais, J.; Tavassoli, A.; Zhang, Y.; Wilson, I. A.; Benkovic, S. J.; Boger, D. L. Design, synthesis, and biological evaluation of simplified α-keto heterocycle, trifluoromethyl ketone, and formyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase Bioorg. Med. Chem. 2003, 11, 4487-4501 and references therein
18. Chikashita, H.; Ishibaba, M.; Ori, K.; Itoh, K. General reactivity of 2-lithiobenzothiazole to various electrophiles and the use as a formyl anion equivalent in the synthesis of α-hydroxy carbonyl compounds Bull. Chem. Soc. Jpn. 1988, 61, 3637-3648
19. Bordeleau, M.-E.; Mori, A.; Oberer, M.; Lindqvist, L.; Chard, L. S.; Higa, T.; Belsham, G. J.; Wagner, G.; Tanaka, J.; Pelletier, J. Functional characterization of IREDes by an inhibitor of the RNA helicase eIF4A Nature Chem. Biol. 2006, 2, 213-220
20. Graff, J. R.; Konicek, B. W.; Carter, J. H.; Marcusson, E. G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy Cancer Res. 2008, 68, 631-634